Per- and polyfluoroalkyl substances: evaluation of liver effects using in vivo data - PFAS/2023/06

Table 2 Lowest POD for PFAS based on liver effects - PFSAs

In this guide

In this guide

- 1. Introduction, Background and Literature Search PFAS/2023/06
- 2. In vivo liver toxicity studies PFAS/2023/06
- 3. Endpoints Investigated and Summary of Results PFAS/2023/06
- 4. Liver Weight PFAS/2023/06
- 5. Clinical chemistry- PFAS/2023/06
- 6. Liver histopathology PFAS/2023/06
- 7. Effects on gene expression PFAS/2023/06
- 8. Serum/plasma PFAS levels PFAS/2023/06
- 9. Discussion PFAS/2023/06
- 10. Table 1 Lowest POD for PFAS based on liver effects PFCAs
- 11. Table 2 Lowest POD for PFAS based on liver effects PFSAs
- 12. Questions on which the views of the Committee are sought PFAS/2023/06
- 13. List of Abbreviations PFAS/2023/06
- 14. References PFAS/2023/06

This is a paper for discussion. This does not represent the views of the Committee and should not be cited.

Substance / reference / table

Sex, strain and

species NOAEL/LOAEL

mg/kg bw/day (Duration)

Effect at LOAEL

^{*}Derived by contractor; NA - not applicable.

| PFBS Chen et al. (2022) Table 17 | Male C57BL/6 mice, 28 days. | Males: 2 / 104. | ↑ apoptosis ↓ CAT activity Changes in hepatic lipidome. |
|---|---|----------------------------------|---|
| PFHxS Butenhoff et al. (2009) Table 18 Chang et al. (2018) Table 18 | Male Crl:CD®(SD) IGS BR VAF/Plus® 42 days. Male Crl:CD1 mice 42 days. | Males: NA / 0.3. | ↓ serum cholesterol, ↑ centrilobular hypertrophy. |
| PFOS Butenhoff et al. (2012b) Table 19 | Male and female Crl:CD®(SD) IGS BR rats, 104 weeks. | Males/females: 0.024 / 0.098. | Male ↑ hepatocellular centrilobular hypertrophy ↑ cystic hepatocellular Degeneration. Female ↑ hepatocellular periportal vacuolation ↓ serum total cholesterol. |